English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 March 2023, 10:45 JST
Share:
    

Source: Eisai
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan

TOKYO, Mar 2, 2023 - (JCN Newswire) - Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023.

The two companies have been jointly engaged in promotional activities for MS treatments in Japan. However, since a certain objective has been achieved regarding penetration of the products into the Japanese market, the two companies decided to terminate this co-promotion agreement. As a result, Biogen Japan will have full responsibility for all operations related to the products after a transition period between the two companies. Upon termination of this agreement, Biogen will pay Eisai 31 million USD.

The termination of this co-promotion agreement does not impact any of the other agreements between Biogen and Eisai.

For more information, visit www.eisai.com/news/2023/news202315.html.

Contacts:

Biogen Japan Ltd.
MEDIA CONTACT:
Public Relations & CSR Department
MOB: +81-(0)70-1501-4315
TEL: +81-(0)3-3275-1745

Eisai Co., Ltd.
MEDIA CONTACT:
Public Relations Department
TEL: +81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Wednesday, 15 May 2024, 11:19 JST
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Monday, 13 May 2024, 17:06 JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
Thursday, 18 April 2024, 10:53 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, 17 April 2024, 16:17 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
2024年4月17日 10時00分 JST
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575